Bibliography
- Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation–executive summary: a report of the American college of cardiology/American heart association task force on practice guidelines and the european society of cardiology committee for practice guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006;48:854-906
- Reiffel JA. Rate versus rhythm control pharmacotherapy for atrial fibrillation: where are we in 2008? J Atrial Fibrillation 2008;1:31-47
- Calkins H, Brugada J, Packer DL, et al. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2007;4:816-61
- Wijffels MC, Kirchhof CJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995;92:1954-68
- Burashnikov A, Di Diego JM, Zygmunt AC, et al. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 2007;116:1449-57
- Naccarelli GV, Gonzalez MD. Atrial fibrillation and the expanding role of catheter ablation: do antiarrhythmic drugs have a future? J Cardiovasc Pharmacol 2008;52:203-9
- CAST Investigators Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12
- Singh BN. Amiodarone as paradigm for developing new drugs for atrial fibrillation. J Cardiovasc Pharmacol 2008;52:300-5
- Goldschlager N, Epstein AE, Naccarelli GV, et al. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm 2007;4:1250-9
- Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005;293:2634-40
- Pappone C, Radinovic A, Manguso F, et al. Atrial fibrillation progression and management: a 5-year prospective follow-up study. Heart Rhythm 2008;5:1501-7
- Jais P, Cauchemez B, Macle L, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 2008;118:2498-505
- Callans DJ. Apples and oranges: comparing antiarrhythmic drugs and catheter ablation for treatment of atrial fibrillation. Circulation 2008;118:2488-90
- Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33
- Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358:2667-77
- Cain ME, Curtis AB. Rhythm control in atrial fibrillation–one setback after another. N Engl J Med 2008;358:2725-7
- Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004;109:1509-13
- Steinberg JS, Sadaniantz A, Kron J, et al. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004;109:1973-80
- Curtis AB, Gersh BJ, Corley SD, et al. Clinical factors that influence response to treatment strategies in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005;149:645-9
- Savelieva I, Camm J. Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace 2008;10:647-65
- Nattel S, Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Discov 2006;5:1034-49
- Burashnikov A, Antzelevitch C. How do atrial-selective drugs differ from antiarrhythmic drugs currently used in the treatment of atrial fibrillation? J Atrial Fibrillation 2008;1:98-107
- Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol 2008;1:62-73
- Goette A, Bukowska A, Lendeckel U. Non-ion channel blockers as anti-arrhythmic drugs (reversal of structural remodeling). Curr Opin Pharmacol 2007;7:219-24
- Savelieva I, Camm J. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. Nat Clin Pract Cardiovasc Med 2008;5:30-41
- Dobrev D, Friedrich A, Voigt N, et al. The G protein-gated potassium current IK,ACh is constitutively active in patients with chronic atrial fibrillation. Circulation 2005;112:3697-706
- Ehrlich JR, Nattel S. Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope? Curr Opin Cardiol 2009;24:50-5
- Cha TJ, Ehrlich JR, Chartier D, et al. Kir3-based inward rectifier potassium current: potential role in atrial tachycardia remodeling effects on atrial repolarization and arrhythmias. Circulation 2006;113:1730-7
- Hashimoto N, Yamashita T, Tsuruzoe N. Tertiapin, a selective IK,ACh blocker, terminates atrial fibrillation with selective atrial effective refractory period prolongation. Pharmacol Res 2006;54:136-41
- Guerra JM, Everett TH, Lee KW, et al. Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation. Circulation 2006;114:110-8
- Shiroshita-Takeshita A, Sakabe M, Haugan K, et al. Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs. Circulation 2007;115:310-8
- Ford JW, Milnes JT. New drugs targeting the cardiac ultra-rapid delayed-rectifier current (I Kur): rationale, pharmacology and evidence for potential therapeutic value. J Cardiovasc Pharmacol 2008;52:105-20
- Fedida D. Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent. Expert Opin Investig Drugs 2007;16:519-32
- Carlsson L, Chartier D, Nattel S. Characterization of the in vivo and in vitro electrophysiological effects of the novel antiarrhythmic agent AZD7009 in atrial and ventricular tissue of the dog. J Cardiovasc Pharmacol 2006;47:123-32
- Blaauw Y, Gogelein H, Tieleman RG, et al. “Early” class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation 2004;110:1717-24
- Christ T, Wettwer E, Voigt N, et al. Pathology-specific effects of the IKur/Ito/IK,ACh blocker AVE0118 on ion channels in human chronic atrial fibrillation. Br J Pharmacol 2008;154:1619-30
- Burashnikov A, Antzelevitch C. Can inhibition of IKur promote atrial fibrillation? Heart Rhythm 2008;5:1304-9
- Feng J, Xu D, Wang Z, et al. Ultrarapid delayed rectifier current inactivation in human atrial myocytes: properties and consequences. Am J Physiol 1998;275:H1717-25
- Van Wagoner DR, Pond AL, McCarthy PM, et al. Outward K + current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation. Circ Res 1997;80:772-81
- Wettwer E, Hala O, Christ T, et al. Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation 2004;110:2299-306
- Burashnikov A, Antzelevitch C. New pharmacological strategies for the treatment of atrial fibrillation. Ann Noninvasive Electrocardiol 2009 In press
- Olson TM, Alekseev AE, Liu XK, et al. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum Mol Genet 2006;15:2185-91
- Burashnikov A, Mannava S, Antzelevitch C. Transmembrane action potential heterogeneity in the canine isolated arterially-perfused atrium: effect of IKr and Ito/IKur block. Am J Physiol 2004;286:H2393-400
- Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002;415:219-26
- Burashnikov A, Di Diego JM, Sicouri S, et al. Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. Heart Rhythm 2008;5:1735-42
- Burashnikov A, Di Diego JM, Zygmunt AC, et al. A trial-selective sodium channel block as a strategy for suppression of atrial fibrillation. Ann NY Acad Sci 2008;1123:105-12
- Burashnikov A, Antzelevitch C. Atrial-selective sodium channel blockers: do they exist? J Cardiovasc Pharmacol 2008;52:121-8
- Burashnikov A, Belardinelli L, Antzelevitch C. Ranolazine and propafenone both suppress atrial fibrillation but ranolazine unlike propafenone does it without prominent effects on ventricular myocardium. Heart Rhythm 2007;4:S163
- Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiologic effects of ranolazine: a novel anti-anginal agent with antiarrhythmic properties. Circulation 2004;110:904-10
- Kodama I, Kamiya K, Toyama J. Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. Am J Cardiol 1999;84:20R-8R
- Goldstein RN, Khrestian C, Carlsson L, et al. Azd7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J Cardiovasc Electrophysiol 2004;15:1444-50
- Burashnikov A, Barajas-Martinez H, Hu D, et al. The atrial-selective potassium channel blocker AVE0118 prolongs effective refractory period in canine atria by inhibiting sodium channels [abstract]. Heart Rhythm 2009;6:S98
- Regan CP, Kiss L, Stump GL, et al. Atrial antifibrillatory effects of structurally distinct IKur blockers 3-[(dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in dogs with underlying heart failure. J Pharmacol Exp Ther 2008;324:322-30
- Courtemanche M, Ramirez RJ, Nattel S. Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. Cardiovasc Res 1999;42:477-89
- Wirth KJ, Brendel J, Steinmeyer K, et al. In vitro and in vivo effects of the atrial selective antiarrhythmic compound AVE1231. J Cardiovasc Pharmacol 2007;49:197-206
- Li GR, Wang HB, Qin GW, et al. Acacetin, a natural flavone, selectively inhibits human atrial repolarization potassium currents and prevents atrial fibrillation in dogs. Circulation 2008;117:2449-57
- Singh BN, Vaughan-Williams EM. The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol 1970;39:657-67
- Kodama I, Toyama J, Takanaka C, et al. Block of activated and inactivated sodium channels by class I antiarrhythmic drugs studied by using the maximum upstroke velocity (Vmax) of action potential in guinea-pig cardiac muscles. J Mol Cell Cardiol 1987;19:367-77
- Langenfeld H, Weirich J, Kohler C, et al. Comparative analysis of the action of class I antiarrhythmic drugs (lidocaine, quinidine, and prajmaline) in rabbit atrial and ventricular myocardium. J Cardiovasc Pharmacol 1990;15:338-45
- Nemeth M, Virag L, Hala O, et al. The cellular electrophysiological effects of tedisamil in human atrial and ventricular fibers. Cardiovasc Res 1996;31:246-8
- Persson F, Andersson B, Duker G, et al. Functional effects of the late sodium current inhibition by AZD7009 and lidocaine in rabbit isolated atrial and ventricular tissue and Purkinje fibre. Eur J Pharmacol 2007;558:133-43
- Hondeghem LM, Katzung BG. Mechanism of action of antiarrhythmic drugs. In: Sperelakis N, editors, Physiology and Pathophysiology of the Heart. Third Edition. Kluwer Academic Publishers, 1995. p. 589-603
- Whalley DW, Wendt DJ, Grant AO. Basic concepts in cellular cardiac electrophysiology: part II: block of ion channels by antiarrhythmic drugs. PACE 1995;18:1686-704
- Spinelli W, Parsons RW, Colatsky TJ. Effects of WAY-123,398, a new Class-III antiarrhythmic agent, on cardiac refractoriness and ventricular fibrillation threshold in anesthetized dogs – a comparison with UK-68798, e-4031, and DL- Sotalol. J Cardiovasc Pharmacol 1992;20:913-22
- Wiesfeld AC, De Langen CD, Crijns HJ, et al. Rate-dependent effects of the class III antiarrhythmic drug almokalant on refractoriness in the pig. J Cardiovasc Pharmacol 1996;27:594-600
- Baskin EP, Lynch JJ Jr. Differential atrial versus ventricular activities of class III potassium channel blockers. J Pharmacol Exp Ther 1998;285:135-42
- Stump GL, Wallace AA, Regan CP, et al. In vivo antiarrhythmic and cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide. J Pharmacol Exp Ther 2005;315:1362-7
- Wang J, Feng J, Nattel S. Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide. Circulation 1994;90:2032-40
- Echt DS, Berte LE, Clusin WT, et al. Prolongation of the human monophasic action potential by sotalol. Am J Cardiol 1982;50:1082-6
- Buchanan LV, LeMay RJ, Walters RR, et al. Antiarrhythmic and electrophysiologic effects of intravenous ibutilide and sotalol in the canine sterile pericarditis model. J Cardiovasc Electrophysiol 1996;7:113-9
- Antzelevitch C, Shimizu W, Yan GX, et al. The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol 1999;10:1124-52
- Burashnikov A, Antzelevitch C. Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation. PACE 2006;29:290-5
- Carmeliet E, Mubagwa K. Antiarrhythmic drugs and cardiac ion channels: mechanisms of action. Prog Biophys Mol Biol 1998;70:1-72
- Wang GK, Calderon J, Wang SY. State- and use-dependent block of muscle Nav1.4 and neuronal Nav1.7 noltage-gated Na + channel isoforms by ranolazine. Mol Pharmacol 2008;73:940-8
- Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res 1997;35:13-29
- Golod DA, Kumar R, Joyner RW. Determinants of action potential initiation in isolated rabbit atrial and ventricular myocytes. Am J Physiol 1998;274:H1902-13
- Hiroe K, Hisatome I, Tanaka Y, et al. Tonic block of the Na + current in single atrial and ventricular guinea-pig myocytes, by a new antiarrhythmic drug, Ro 22-9194. Fundam Clin Pharmacol 1997;11:402-7
- Li GR, Lau CP, Shrier A. Heterogeneity of sodium current in atrial vs epicardial ventricular myocytes of adult guinea pig hearts. J Mol Cell Cardiol 2002;34:1185-94
- Kneller J, Kalifa J, Zou R, et al. Mechanisms of atrial fibrillation termination by pure sodium channel blockade in an ionically-realistic mathematical model. Circ Res 2005;96:e35-e47
- Comtois P, Sakabe M, Vigmond EJ, et al. Mechanisms of atrial fibrillation termination by rapidly unbinding Na + channel blockers. Insights from mathematical models and experimental correlates. Am J Physiol Heart Circ Physiol 2008;295:H1489-H1504
- Kumagai K, Nakashima H, Tojo H, et al. Pilsicainide for atrial fibrillation. Drugs 2006;66:2067-73
- Wu LM, Orikabe M, Hirano Y, et al. Effects of Na + channel blocker, pilsicainide, on HERG current expressed in HEK-293 cells. J Cardiovasc Pharmacol 2003;42:410-8
- Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007;116:1647-52
- Murdock DK, Overton N, Kersten M, et al. The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol J 2008;8:175-81
- Crijns HJ, Van GI, Walfridsson H, et al. Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. Heart Rhythm 2006;3:1321-31
- Geller JC, Egstrup K, Kulakowski P, et al. Rapid conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. J Clin Pharmacol 2009;49:312-22
- Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation. A phase 3, randomized, placebo-controlled trial. Circulation 2008;117:1518-25
- Chaitman BR. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation 2006;113:2462-72
- Antzelevitch C, Belardinelli L, Wu L, et al. Electrophysiologic properties and antiarrhythmic actions of a novel anti-anginal agent. J Cardiovasc Pharmacol Ther 2004;9(Suppl 1):S65-S83
- Maltsev VA, Sabbah HN, Undrovinas AI. Late sodium current is a novel target for amiodarone: studies in failing human myocardium. J Mol Cell Cardiol 2001;33:923-32
- Antzelevitch C. Electrical heterogeneity, cardiac arrhythmias, and the sodium channel. Circ Res 2000;87:964-5
- Shryock JC, Belardinelli L. Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium. Br J Pharmacol 2008;153:1128-32
- Blaauw Y, Schotten U, van HA, et al. Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat. Cardiovasc Res 2007;75:89-98
- Duytschaever M, Blaauw Y, Allessie M. Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs. Cardiovasc Res 2005;67:69-76
- Linz DK, Afkham F, Itter G, et al. Effect of atrial electrical remodeling on the efficacy of antiarrhythmic drugs: comparison of amiodarone with IKr- and Ito/IKur-blockade in vivo strial electrical remodeling and antiarrhythmic drugs. J Cardiovasc Electrophysiol 2007;18:1313-20
- Gaspo R, Bosch RF, Bou-Abboud E, et al. Tachycardia-induced changes in Na + current in a chronic dog model of atrial fibrillation. Circ Res 1997;81:1045-52
- Bosch RF, Zeng X, Grammer JB, et al. Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res 1999;44:121-31
- Eijsbouts S, Ausma J, Blaauw Y, et al. Serial cardioversion by class IC drugs during 4 months of persistent atrial fibrillation in the goat. J Cardiovasc Electrophysiol 2006;17:648-54
- Billman GE, Kukielka M. Novel transient outward and ultra-rapid delayed rectifier current antagonist, AVE0118, protects against ventricular fibrillation induced by myocardial ischemia. J Cardiovasc Pharmacol 2008;51:352-8
- Antzelevitch C. Ranolazine: a new antiarrhythmic agent for patients with non-ST-segment elevation acute coronary syndromes? Nat Clin Pract Cardiovasc Med 2008;5:248-9
- Brackenbury WJ, Isom LL. Voltage-gated Na + channels: potential for b subunits as therapeutic targets. Expert Opin Ther Targets 2008;12:1191-203
- Fahmi AI, Patel M, Stevens EB, et al. The sodium channel b-subunit SCN3b modulates the kinetics of SCN5a and is expressed heterogeneously in sheep heart. J Physiol 2001;537:693-700
- Ko SH, Lenkowski PW, Lee HC, et al. Modulation of Nav1.5 by b1- and b3-subunit co-expression in mammalian cells. Pflugers Arch 2005;449:403-12
- Gaborit N, Le BS, Szuts V, et al. Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart. J Physiol 2007;582:675-93
- Hu D, Zygmunt AC, Burashnikov A, et al. Sodium channel of canine atrial and ventricular cells differ with respect to voltage dependence of inactivation [abstract]. Heart Rhythm 2007;4:S148
- Lopez-Santiago LF, Meadows LS, Ernst SJ, et al. Sodium channel Scn1b null mice exhibit prolonged QT and RR intervals. J Mol Cell Cardiol 2007;43:636-47
- Deschenes I, Armoundas AA, Jones SP, et al. Post-transcriptional gene silencing of KChIP2 and Navb1 in neonatal rat cardiac myocytes reveals a functional association between Na and Ito currents. J Mol Cell Cardiol 2008;45:336-46
- Ellinor PT, Nam EG, Shea MA, et al. Cardiac sodium channel mutation in atrial fibrillation. Heart Rhythm 2008;5:99-105
- Darbar D, Kannankeril PJ, Donahue BS, et al. Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. Circulation 2008;117:1927-35
- Chen LY, Ballew JD, Herron KJ, et al. A common polymorphism in SCN5A is associated with lone atrial fibrillation. Clin Pharmacol Ther 2007;81:35-41
- Kusano KF, Taniyama M, Nakamura K, et al. Atrial fibrillation in patients with Brugada syndrome relationships of gene mutation, electrophysiology, and clinical backgrounds. J Am Coll Cardiol 2008;51:1169-75
- Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med 2007;356:935-41
- Chen PS. Neural mechanisms of atrial fibrillation. Heart Rhythm 2006;3:1373-7
- Singh BN. Amiodarone: a multifaceted antiarrhythmic drug. Curr Cardiol Rep 2006;8:349-55
- Nabar A, Rodriguez LM, Timmermans C, et al. Class IC antiarrhythmic drug induced atrial flutter: electrocardiographic and electrophysiological findings and their importance for long term outcome after right atrial isthmus ablation. Heart 2001;85:424-9
- Vincent GM. Atrial arrhythmias in the inherited long QT syndrome: laboratory quirk or clinical arrhythmia? J Cardiovasc Electrophysiol 2003;14:1034-5
- Alboni P, Botto GL, Baldi N, et al. Outpatient treatment of recent-onset atrial fibrillation with the “pill-in-the-pocket” approach. N Engl J Med 2004;351:2384-91
- Furukawa T, Koumi S, Sakakibara Y, et al. An analysis of lidocaine block of sodium current in isolated human atrial and ventricular myocytes. J Mol Cell Cardiol 1995;27:831-46
- Ahmmed GU, Hisatome I, Kurata Y, et al. Analysis of moricizine block of sodium current in isolated guinea-pig atrial myocytes. Atrioventricular difference of moricizine block. Vascul Pharmacol 2002;38:131-41